| Gordon K Wolfe, MD | |
|
190 Campus Blvd Ste 100, Winchester, VA 22601-2842 | |
| (540) 536-5980 | |
| (540) 536-5979 |
| Full Name | Gordon K Wolfe |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 46 Years |
| Location | 190 Campus Blvd Ste 100, Winchester, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649238437 | NPI | - | NPPES |
| 006053823 | Medicaid | VA | |
| 0071689000 | Medicaid | WV | |
| 110024326 | Other | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 0101042299 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Winchester Medical Center | Winchester, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Physician Enterprise Inc | 9931268091 | 205 |
News Archive
FDA on Monday said Roche's organ-rejection drug CellCept increases the risk of birth defects and miscarriage during the first trimester of pregnancy, Reuters reports. CellCept prevents organ rejection among kidney, liver and heart transplant recipients.
The Contra Costa Times: "The effort to overhaul the nation's health care system has so far skirted the issue of tort reform, intensifying debate over the role malpractice lawsuits play in increasing premiums." Critics say the new health reform law does not do enough to address the high costs of medical lawsuits, but other experts say that malpractice suits do not contribute to increasing health costs.
My research these days is generally classified as structural biology, although as I trained in chemistry. I specialize in nuclear magnetic resonance (NMR) applied to biological problems. Our lab is very interested in studying mammalian proteins, particularly systems involved in cancer, in order to try to understand mechanisms to provide that information for our collaborators, and for the general knowledge of the community as well.
Myeloma UK is launching a new research program to continue support for patient-centric myeloma clinical trials in the UK, the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Programme.
› Verified 7 days ago
| Entity Name | Winchester Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679711261 PECOS PAC ID: 0244134021 Enrollment ID: O20031124000061 |
News Archive
FDA on Monday said Roche's organ-rejection drug CellCept increases the risk of birth defects and miscarriage during the first trimester of pregnancy, Reuters reports. CellCept prevents organ rejection among kidney, liver and heart transplant recipients.
The Contra Costa Times: "The effort to overhaul the nation's health care system has so far skirted the issue of tort reform, intensifying debate over the role malpractice lawsuits play in increasing premiums." Critics say the new health reform law does not do enough to address the high costs of medical lawsuits, but other experts say that malpractice suits do not contribute to increasing health costs.
My research these days is generally classified as structural biology, although as I trained in chemistry. I specialize in nuclear magnetic resonance (NMR) applied to biological problems. Our lab is very interested in studying mammalian proteins, particularly systems involved in cancer, in order to try to understand mechanisms to provide that information for our collaborators, and for the general knowledge of the community as well.
Myeloma UK is launching a new research program to continue support for patient-centric myeloma clinical trials in the UK, the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Programme.
› Verified 7 days ago
| Entity Name | Winchester Pulmonary & Internal Medicine Associates Pc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316973449 PECOS PAC ID: 4284608464 Enrollment ID: O20040824000061 |
News Archive
FDA on Monday said Roche's organ-rejection drug CellCept increases the risk of birth defects and miscarriage during the first trimester of pregnancy, Reuters reports. CellCept prevents organ rejection among kidney, liver and heart transplant recipients.
The Contra Costa Times: "The effort to overhaul the nation's health care system has so far skirted the issue of tort reform, intensifying debate over the role malpractice lawsuits play in increasing premiums." Critics say the new health reform law does not do enough to address the high costs of medical lawsuits, but other experts say that malpractice suits do not contribute to increasing health costs.
My research these days is generally classified as structural biology, although as I trained in chemistry. I specialize in nuclear magnetic resonance (NMR) applied to biological problems. Our lab is very interested in studying mammalian proteins, particularly systems involved in cancer, in order to try to understand mechanisms to provide that information for our collaborators, and for the general knowledge of the community as well.
Myeloma UK is launching a new research program to continue support for patient-centric myeloma clinical trials in the UK, the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Programme.
› Verified 7 days ago
| Entity Name | Valley Physician Enterprise Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538316203 PECOS PAC ID: 9931268091 Enrollment ID: O20081104000278 |
News Archive
FDA on Monday said Roche's organ-rejection drug CellCept increases the risk of birth defects and miscarriage during the first trimester of pregnancy, Reuters reports. CellCept prevents organ rejection among kidney, liver and heart transplant recipients.
The Contra Costa Times: "The effort to overhaul the nation's health care system has so far skirted the issue of tort reform, intensifying debate over the role malpractice lawsuits play in increasing premiums." Critics say the new health reform law does not do enough to address the high costs of medical lawsuits, but other experts say that malpractice suits do not contribute to increasing health costs.
My research these days is generally classified as structural biology, although as I trained in chemistry. I specialize in nuclear magnetic resonance (NMR) applied to biological problems. Our lab is very interested in studying mammalian proteins, particularly systems involved in cancer, in order to try to understand mechanisms to provide that information for our collaborators, and for the general knowledge of the community as well.
Myeloma UK is launching a new research program to continue support for patient-centric myeloma clinical trials in the UK, the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Programme.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gordon K Wolfe, MD 220 Campus Blvd Ste 100, Winchester, VA 22601-2896 Ph: (540) 536-5100 | Gordon K Wolfe, MD 190 Campus Blvd Ste 100, Winchester, VA 22601-2842 Ph: (540) 536-5980 |
News Archive
FDA on Monday said Roche's organ-rejection drug CellCept increases the risk of birth defects and miscarriage during the first trimester of pregnancy, Reuters reports. CellCept prevents organ rejection among kidney, liver and heart transplant recipients.
The Contra Costa Times: "The effort to overhaul the nation's health care system has so far skirted the issue of tort reform, intensifying debate over the role malpractice lawsuits play in increasing premiums." Critics say the new health reform law does not do enough to address the high costs of medical lawsuits, but other experts say that malpractice suits do not contribute to increasing health costs.
My research these days is generally classified as structural biology, although as I trained in chemistry. I specialize in nuclear magnetic resonance (NMR) applied to biological problems. Our lab is very interested in studying mammalian proteins, particularly systems involved in cancer, in order to try to understand mechanisms to provide that information for our collaborators, and for the general knowledge of the community as well.
Myeloma UK is launching a new research program to continue support for patient-centric myeloma clinical trials in the UK, the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Programme.
› Verified 7 days ago
Dr. Raveen Chawla, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1880 Amherst Street, Suite 100 And Suite 200, Winchester, VA 22601 Phone: 540-662-0306 Fax: 855-264-2066 | |
Dr. Neal S Gaither, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1880 Amherst Street, Suite 100 And Suite 200, Winchester, VA 22601 Phone: 540-662-0306 Fax: 855-264-2066 | |
Dr. Lee Resta, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 400 Campus Blvd Ste 100, Winchester, VA 22601 Phone: 540-662-1108 | |
Kristine Gade Reed, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 400 Campus Blvd., Suite 100, Winchester, VA 22601 Phone: 540-662-1108 Fax: 540-450-2244 | |
Dr. David Jack Lecronier, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 190 Campus Blvd Ste 201, Winchester, VA 22601 Phone: 540-536-5980 Fax: 540-536-5979 | |
T. Glen Bouder, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8874 Fax: 540-536-7847 | |
Dr. Manish J Lakhani, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1880 Amherst Street, Suite 100 And Suite 200, Winchester, VA 22601 Phone: 540-662-0306 Fax: 855-264-2066 |